Depletion of high-density lipoprotein and appearance of triglyceride-rich low-density lipoprotein in a japanese patient with FIC1 deficiency manifesting benign recurrent intrahepatic cholestasis

Journal of Pediatric Gastroenterology and Nutrition

Volumn 45, Issue 1, 2007, Pages 96-105

  Nagasaka, Hironori ^a,b   Chiba, Hitoshi ^b   Hui, Shu Ping ^b   Takikawa, Hajime ^c   Miida, Takashi ^d   Takayanagi, Masaki ^a   Yorifuji, Tohru ^e   Hasegawa, Makoto ^f   Ota, Akemi ^g   Hirano, Ken Ichi ^g   Kikuchi, Hideaki ^h   Tsukahara, Hirokazu ⁱ   Kobayashi, Kunihiko ^b  

^a CHIBA CHILDREN'S HOSPITAL   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^c TEIKYO UNIVERSITY   (Japan)

^d NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^e KYOTO UNIVERSITY HOSPITAL   (Japan)

^f UNIVERSITY OF TSUKUBA   (Japan)

^g OSAKA UNIVERSITY   (Japan)

^h Obihiro Kosei Hospital   (Japan)

ⁱ UNIVERSITY OF FUKUI HOSPITAL   (Japan)

Author keywords

ATP8B1 gene; Farnesoid X receptor; FIC1; Hepatic triglyceride lipase; High density lipoprotein; Intrahepatic cholestasis; Lecithin:cholesterol acyltransferase; Low density lipoprotein

Indexed keywords

CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ESTER TRANSFER PROTEIN; FARNESOID X RECEPTOR; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN X; LIVER PROTEIN; LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE;

ADULT; ARTICLE; CASE REPORT; CONTROLLED STUDY; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HYPERCHOLESTEROLEMIA; INTRAHEPATIC CHOLESTASIS; LIPOPROTEIN METABOLISM; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS;

ADENOSINE TRIPHOSPHATASES; ADULT; APOLIPOPROTEINS E; CHOLESTASIS, INTRAHEPATIC; CHOLESTEROL, HDL; HUMANS; HYPERBILIRUBINEMIA; JAPAN; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIVER; MALE; PANCREATITIS; PROTEIN BIOSYNTHESIS; RECURRENCE; TRIGLYCERIDES;

EID: 34347358580     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3180331df9     Document Type: Article

References (42)

1. Summerskill WHJ, Walshe JM. Benign recurrent intrahepatic obstructive cholestasis. Lancet 1959; 686-90.
2. Brenard R, Geubel AP, Benhamou JP. Benign recurrent intrahepatic cholestasis: a report of 26 cases. J Clin Gastroenterol 1989;11:546-51.
3. Bijleveld CM, Vonk RJ, Kuipers F, et al. Benign recurrent intrahepatic cholestasis: altered bile acid metabolism. Gastroenterology 1989;97:427-32.
4. Bijleveld CM, Vonk RJ, Kuipers F, et al. Benign recurrent intrahepatic cholestasis: a long-term follow-up study of two patients. Hepatology 1989;9:532-7.
5. van Mil SW, Klomp LW, Bull LN, et al. FIC1 disease: a spectrum of intrahepatic cholestasis. Semin Liver Dis 2001;21:535-44.
6. Bull L, Freimer N, Czubkowski P, et al. Clinical and biochemical features of FIC1 (ATP8B1) and BSEP (ABCB11) disease. Hepatology 2002;36:310A.
7. van Mil SW, van der Woerd WL, van der Brugge G, et al. Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11. Gastroenterology 2004;127:379-84.
8. Tygstrup N, Steig BA, Juijn JA, et al. Recurrent familial intrahepatic cholestasis in the Faeroe Islands: phenotypic heterogeneity but genetic homogeneity. Hepatology 1999;29:506-8.
9. Harry DS, Owen JS, Mclntyre N. Plasma lipoproteins and the liver. In: Wright R, Millward-SadLer GH, Alberti KGMM, et al. (eds.). Liver and Biliary Disease. 2nd ed. London: Bailliere-Tindall & Saunders; 1985. pp. 65-85.
10. Nagasaka H, Yorifuji T, Egawa H, et al. Evaluation of risk for atherosclerosis in Alagille syndrome and progressive familial intrahepatic cholestasis: two congenital cholestatic diseases with different lipoprotein metabolism. J Pediatr 2005;146:329-35.
11. Chiba H, Osaka T, Iwasaki N, et al. Spurious elevation of serum high-density lipoprotein cholesterol in patients with cholestatic liver diseases. Biochem Med Metab Biol 1991;46:329-43.
12. Jahn CE, Schaeffer EJ, Taam LA, et al. Lipoprotein abnormalities in primary biliary cirrhosis: association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology 1985;89:1266-78.
13. Hiraoka H, Yamashita S, Matsuzawa Y, et al. Decrease of hepatic triglyceride lipase levels and increase of cholesteryl ester transfer protein levels in patients with primary biliary cirrhosis: relationship to abnormalities in high-density lipoprotein. Hepatology 1993;18:103-10.
14. Aly A, Carlson K, Johansson C, et al. Lipoprotein abnormalities in patients with early primary cirrhosis. Eur J Clin Invest 1984;14:156-62.
15. Davit-Spraul A, Pourci ML, Atger V, et al. Abnormal lipoprotein pattern in patients with Alagille syndrome depends on icterus severity. Gastroenterology 1996;111:1023-32.
16. Kostner GM, Laggner P, Prexl HJ, et al. Investigation of the abnormal low-density lipoproteins occurring in patients with obstructive jaundice. Biochem J 1976;157:401-7.
17. Muller P, Felin R, Lambrecht J, et al. Hypertriglyceridaemia secondary to liver disease. Eur J Clin Invest 1974;4:419-28.
18. Manzato E, Fellin R, Baggio G, et al. Formation of lipoprotein-X: its relationship to bile compounds. J Clin Invest 1976;57:1248-60.
19. Soros P, Bottcher J, Maschek H, et al. Lipoprotein-X in patients with cirrhosis: its relationship to cholestasis and hypercholesterolemia. Hepatology 1998;28:1199-205.
20. Claudel T, Sturm E, Duez H, et al. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest 2002;109:961-71.
21. Masson D, Lagrost L, Athias A, et al. Expression of the pregnane X receptor in mice antagonizes the cholic acid-mediated changes in plasma lipoprotein profile. Arterioscler Thromb Vasc Biol 2005;25:2164-9.
22. Poittevin M, Legrand A, Chappuis P, et al. Determination of the serum concentration of lipoprotein X. Ann Biol Clin (Paris) 1981;39:361-7.
23. Kotani K, Maekawa M, Kanno T, et al. Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum. Biochem Biophys Acta 1994;1215:121-5.
24. Kato H, Nakanishi T, Arai H, et al. Purification, microheterogeneneity, and stability of human lipid transfer protein. J Biol Chem 1989;264:4082-7.
25. Kiyohara T, Kiriyama R, Zamma S, et al. Enzyme immunoassay for cholesteryl ester transfer protein in human serum. Clin Chim Acta 1998;271:109-18.
26. Nozaki S, Kubo M, Matsuzawa Y, et al. Sensitive non-radioisotopic method for measuring lipoprotein lipase and hepatic triglyceride lipase in human post-heparin plasma. Clin Chem 1984;30:748-51.
27. Ikeda Y, Takagi A, Ohkaru Y, et al. A sandwich-enzyme immunoassay for the quantification of lipoprotein lipase and hepatic triglyceride lipase in human postheparin plasma using monoclonal antibodies to the corresponding enzymes. J Lipid Res 1990;31:1911-24.
28. Guerin M, Dolphin PJ, Chapman MJ. Familial lecithin:cholesterol acyltransferase deficiency: further resolution of lipoprotein particle heterogeneity in the low-density interval. Atherosclerosis 1993;104:195-212.
29. Santamarina-Fojo S, Lambert G, Hoeg JM, et al. Lecithin-cholesterol acyltransferase: role in lipoprotein metabolism, reverse cholesterol transport, and atherosclerosis. Curr Opin Lipidol 2000;11:267-75.
30. Vanloo B, Peelman F, Duschuymere K, et al. Relationship between structure and biochemical phenotype of lecithin:cholesterol acyltransferase (LCAT) mutants causing fish-eye disease. J Lipid Res 2000;41:752-61.
31. Knudsen P, Antikainen M, Uusi-Oukari M, et al. Heterozygous hepatic lipase deficiency, due to two missense mutations R186H and L334F, in the HL gene. Atherosclerosis 1997;128:165-74.
32. Breckenridge WC, Little JA, Alaupovic P, et al. Lipoprotein abnormalities associated with a familial deficiency of hepatic lipase. Atherosclerosis 1982;45:161-79.
33. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995;36:211-28.
34. Cox DW, Breckenridge WC, Little JA. Inheritance of apolipoprotein C-II deficiency with hypertriglyceridemia and pancreatitis. N Engl J Med 1978;299:1421-4.
35. Feoli-Fonseca JC, Levy E, Godart M, et al. Familial lipoprotein lipase deficiency in infancy: clinical, biochemical, and molecular study. J Pediatr 1998;133:417-23.
36. van Mil SW, van Oort MM, van den Berg IE, et al. Fic1 is expressed at apical membranes of different epithelial cells in the digestive tract and is induced in the small intestine during postnatal development of mice. Pediatr Res 2004;56:981-7.
37. Floren CH. Apolipoprotein E in hepatocellular liver disease. Scand J Clin Lab Invest 1988;48:199-203.
38. Brown MS, Goldstein JL. Lipoprotein receptors in the liver: control signals for plasma cholesterol traffic. J Clin Invest 1983;72:743-7.
39. Angelin B, Raviola CA, Innerarity TL. Regulation of lipoprotein receptors in the dog: rapid regulation of apolipoprotein B, E receptors, by intestinal lipoprotein and bile acids. J Clin Invest 1983;71:816-31.
40. Salonen JT, Yla-Herttuala S, Yamamoto R, et al. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992;339:883-7.
41. Holvoet P, Vanhaecke J, Janssens S, et al. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998;98:1487-94.
42. Elferink RP, Ottenhoff R, van Marle J, et al. Class III P-glycoproteins mediate the formation of lipoprotein X in the mouse. J Clin Invest 1998;102:1749-57.